Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT07330830 Sponsor: Centre Hospitalier Universitaire de la Guadeloupe Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT07330830
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older and have been seen in an outpatient clinic or are currently admitted to the liver and digestive department at one of the University Hospitals in Guadeloupe, French Guiana, or Réunion Island.
  • You have been diagnosed with a liver condition called MASLD, which means you have excess fat in your liver along with at least one of the following: being overweight or obese, having type 2 diabetes, or having metabolic syndrome (a combination of conditions such as high blood pressure, high blood sugar, and high cholesterol).
  • You are covered by a social security or health insurance scheme.
  • You are able and willing to give your free, informed, written agreement to take part before any study procedures begin.

Who may not be able to join:

  • You are under 18 years of age.
  • You are unable to give your own informed consent, or you are under legal guardianship or judicial protection.
  • You have another known cause of chronic liver disease, such as hepatitis B, C, or E, certain autoimmune or inflammatory liver conditions, inherited conditions affecting iron or copper storage, a genetic condition affecting a liver protein called alpha-1 antitrypsin, or liver disease caused by alcohol (confirm with trial site).
  • You drink more than 30 grams of alcohol per day if you are a man, or more than 20 grams per day if you are a woman (roughly 2–3 standard drinks per day — confirm with trial site).
  • You are currently pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Moana Gelu-Simeon, MD PhD, CHU de la Guadeloupe

Phone: +590590934667

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de la Guadeloupe
Registry
ClinicalTrials.gov
Start date
26 November 2025
Est. completion
26 November 2027

Where this trial is recruiting

French Guiana Guadeloupe Reunion

Primary endpoints

Allele frequencies of PNPLA3 variants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov